Guy G. G. Brusselle - Epidemiology

Author Information

Guy G. Brusselle is a distinguished researcher specializing in respiratory medicine and epidemiology. He is affiliated with the Department of Respiratory Medicine at Ghent University Hospital in Belgium and also holds a position in the Departments of Epidemiology and Respiratory Medicine at Erasmus Medical Center Rotterdam in the Netherlands. His work primarily focuses on asthma and other respiratory conditions, contributing significantly to the understanding and management of these diseases.

Research Contributions

Guy G. Brusselle has made substantial contributions to the field of respiratory medicine, particularly in the study and management of asthma. His research encompasses various aspects of asthma, including biologic therapies, disease-modifying drugs, and patient characteristics influencing exacerbation risks. Additionally, he has explored related conditions such as chronic rhinosinusitis and interstitial lung disease. His work is pivotal in formulating global strategies for asthma management and understanding the molecular mechanisms underlying respiratory diseases.

Aliases

Throughout his career, Guy G. Brusselle has published under various aliases, including Guy Brusselle, Guy G.o. Brusselle, and G. Brusselle, among others. These variations in his name have appeared across different publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citation Count	17,363
H-Index	71
Total Paper Count	467

Publications:

Global Initiative for Asthma Strategy 2021

DOI: 10.1111/resp.14174

Year: 2022

Biologic Therapies for Severe Asthma.

DOI: 10.1056/NEJMra2032506

Year: 2022

Disease-modifying anti-asthmatic drugs

DOI: 10.1016/S0140-6736(22)00331-2

Year: 2022

Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes.

DOI: 10.1016/j.jaip.2021.10.001

Year: 2021

Mepolizumab for chronic rhinosinusitis with nasal polyps.

DOI: 10.1016/S2213-2600(21)00133-8

Year: 2021

Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma

DOI: 10.1183/13993003.00413-2021

Year: 2021

Beclometasone dipropionate/formoterol maintenance and reliever therapy asthma exacerbation benefit increases with blood eosinophil level

DOI: 10.1183/13993003.040982020

Year: 2021

Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.

DOI: 10.1016/j.semarthrit.2021.07.018

Year: 2021

Effect of ACE1 polymorphism rs1799752 on protein levels of ACE2, the SARS-CoV-2 entry receptor, in alveolar lung epithelium

DOI: 10.1183/23120541.00940-2020

Year: 2021

MiR-223 is increased in lungs of patients with COPD and modulates cigarette smoke-induced pulmonary inflammation.

DOI: 10.1152/ajplung.00252.2021

Year: 2021

Who Should Attend These Events?

What Are the Criteria for a Good Screening Program?

What Technologies are Used in Automated Data Collection?

What Role Do Epidemiologists Play in Water Purification?

Why Use Mixed Methods?

What Are the Challenges Faced by Oncologists in Epidemiological Studies?

What is the Epidemiological Impact of ACE Inhibitors?

How Do Genomic Sequencing Technologies Work?

What Are the Future Challenges?

How Does Contraception Affect Public Health?

Partnered Content Networks

Relevant Topics